[Featured Stock] Cellumed, AI Expansion Across Medical Field... Spotlight on Medical AI Software Development Uptrend

Cellumed is showing strong performance. It is interpreted that this is influenced by the medical artificial intelligence (AI) related stocks showing a super-strong trend.

As of 10:43 AM on the 6th, Cellumed is trading at 3,870 KRW, up 7.35% compared to the previous day.

On this day, as buying demand poured into the medical AI theme, the Ministry of Food and Drug Safety also expressed its intention to support the birth of domestic AI medical devices and strengthen global competitiveness through regulatory reform.

According to the related industry on the 5th, Lee Jeong-rim, head of the Medical Device Review Department at the Ministry of Food and Drug Safety, explained the current status of the establishment and revision of medical device-related approval review guidelines. The Ministry of Food and Drug Safety is known to have identified three tasks: ▲establishing approval review guidelines for generative AIMD (Artificial Intelligence Medical Devices) ▲consulting and support for approval such as clinical trials and verification when entering overseas markets ▲revising guidelines for the application of RWE (Real-World Evidence) in medical devices.

According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the global market size for AI new drug development is expected to grow 6.5 times over five years, from 804.3 billion KRW last year to 5.28 trillion KRW by 2027. As AI emerges as a core means in new drug development, it is expected to grow at an average annual rate of 45.7%.

Meanwhile, Cellumed is strengthening its global competitiveness by integrating AI robot technology with its self-developed patient-specific artificial joint total replacement surgery (PSI). Amid the active adoption of AI in the medical and bio industries recently, Cellumed is known to be promoting the advancement of PSI and software through active cooperation with AI robot companies. Previously, Cellumed completed the development of surgical robot software in collaboration with Curexo.